NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/05/2026
Back to search
Official data from USPTO
ARDENA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
03/06/2026
Classification
Registered
Trademark type
Word
Nice classes
42, 45
Filing date
03/08/2017
Registration date
12/19/2017
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/29/2024
Last transaction
03/06/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
32
Owner location
Mariakerke, BE
Examiner
MMEJE, OBIEZE GINIKANWA
Current location
Historical data usage
Holders and representatives
Holders
Pharmavize nv
Pharmavize nv
Representatives
Clifford D. Hyra Fresh IP PLC
Technical classification
Nice Classes
Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and pharmaceutical development; inspection of pharmaceutical products; research on pharmaceutical products; testing of pharmaceutical products; scientific investigations of pharmaceutical products for medical purposes; pharmaceutical development of drugs; development of pharmaceutical products; medical and pharmaceutical research services; consultancy pertaining to pharmacology; qualitative evaluation of pharmaceuticals; research relating to pharmaceuticals; development of pharmaceutical preparations and medicines; laboratory research regarding pharmaceutical products; research in the field of pharmacogenetics; scientific research in the field of pharmaceutics; testing of the effectiveness of pharmaceutical products; research and development services in the field of biology, gynecology, biotechnology, for others in the pharmaceutical industry; conducting clinical trials for others in the field of pharmaceutical products; research and development in the pharmaceutical field and biotechnology; consultancy relating to research and development in the pharmaceutical field; providing scientific research information in the field of clinical trials of pharmaceuticals; conducting early evaluations in the field of new pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific research; [ providing scientific advice in relation to carbon offsetting; ] scientific testing; research and development services; conducting scientific feasibility studies; scientific analysis, namely, chemical analysis; [ scientific and technological services, namely, design in the field of computer networking hardware, computer datacenter architecture, ] scientific and technological services, namely, scientific research, analysis, testing, in the field of pharmaceuticals; providing scientific information in the field of biology, gynecology, biotechnology; providing of scientific research information in the field of, physics, genetics, pharmaceutical, biotechnology, gynecology; scientific medical research; scientific research for medical purposes; research in the field of physics, bacteriology, gynecology, biotechnology; contract research related to molecular sciences; research relating to molecular sciences; scientific research related to chemistry and biology; providing scientific research information in the field of genetics, physics, pharmaceuticals, biotechnology, organic chemistry
Class 45
Legal consultation and advice; reviewing standards and practices to assure compliance with pharmaceutical laws and regulations
Publications
History of USPTO decisions and trademark events.
34 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/08/2026
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
07/26/2025
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
06/30/2025
INPC
INVALIDATION PROCESSED
06/30/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
03/29/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
07/29/2024
71AG
REGISTERED-SEC.71 ACCEPTED
07/29/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/28/2024
ES71
TEAS SECTION 71 RECEIVED
11/07/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/19/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/12/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/27/2018
FIMP
FINAL DISPOSITION PROCESSED
03/27/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/19/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
12/19/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2017
PUBO
PUBLISHED FOR OPPOSITION
10/03/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/13/2017
RFNP
REFUSAL PROCESSED BY IB
09/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/24/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/23/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/23/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/23/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/23/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/23/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/21/2017
RFRR
REFUSAL PROCESSED BY MPU
08/21/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/18/2017
CNRT
NON-FINAL ACTION WRITTEN
08/17/2017
MAFR
APPLICATION FILING RECEIPT MAILED
08/11/2017
DOCK
ASSIGNED TO EXAMINER
08/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/07/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/03/2017
Continuous trademark protection
Get notified about every new filing that threatens ARDENA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.